Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Truist Securities Maintains Buy on DexCom, Lowers Price Target to $94

Author: Benzinga Newsdesk | October 15, 2025 11:11am
Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $102 to $94.

Posted In: DXCM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist